Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models

Anti-Cancer Drugs

Volumn 15, Issue 5, 2004, Pages 503-512

  Higgins, Brian ^a   Kolinsky, Kenneth ^a   Smith, Melissa ^a   Beck, Gordon ^a   Rashed, Mohammad ^a   Adames, Violeta ^a   Linn, Michael ^a   Wheeldon, Eric ^a   Gand, Laurent ^b   Birnboeck, Herbert ^b   Hoffmann, Gerhard ^b  

^a HOFFMANN LA ROCHE INC   (United States)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Cisplatin; Epidermal growth factor receptor; Erlotinib; Gemcitabine; Lung cancer xenograft; Non small cell lung cancer

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEMCITABINE; PROTEIN TYROSINE KINASE INHIBITOR;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPSY; CANCER CHEMOTHERAPY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; GROWTH INHIBITION; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR REGRESSION; XENOGRAFT;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CISPLATIN; DEOXYCYTIDINE; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TIME FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 2942511506     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000127664.66472.60     Document Type: Article

References (20)

1. Ciardiello TG. Anti-epidermal growth factor receptor drugs in cancer therapy. Expert Opin Invest Drugs 2002; 11:755-768.
2. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19:183-232.
3. Rajkumar SV, Adjei AA. A review of the pharmacology and clinical activity of new chemotherapeutic agents in lung cancer. Cancer Treat Rev 1998; 24:35-53.
4. Bunn Jr PA, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 1998; 4:1087-1100.
5. ten Bokkel Huinink WW, Bergman B, Chemaissani A, Dornoff W, Drings P, Kellokumpu-Lehtinen PL, et al. Single-agent gemcitabine: an active and better-tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer. Lung Cancer 1999; 26:85-94.
6. Giaccone G, Splinter TA, Debruyne C, Kho GS, Lianes P, van Zandwijk N, et al. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 1998; 16:2133-2141.
7. Peters GJ, Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Braakhuis BJ. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 1995; 22(4 suppl 11):72-79.
8. Pollack VA, Savage DM, Baker DA, Tsaparikos KE, Sloan DE, Moyer JD, et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 1999; 291:739-748.
9. Moyer JD, Barbacci EG, Iwata KK, Arnold L, Boman B, Cunningham A, et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997; 57:4838-4848.
10. Perez-Soler R, Chachoua A, Huberman M, Karp D, Rigas J, Hammond L, et al. A Phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2001; 20:310a (abstr 1235).
11. Bianco C, Tortora G, Bianco R, Caputo R, Veneziani BM, Caputo R, et al. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res 2002; 8: 3250-3258.
12. Lee M, Draoui M, Zia F, Gazdar A, Oie H, Bepler G, et al. Epidermal growth factor receptor monoclonal antibodies inhibit the growth of lung cancer cell lines. J Natl Cancer Inst Monogr 1992; 13: 117-123.
13. Hoang T, Kim K, Jaslowski A, Koch P, Beatty P, McGovern J, et al. Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer. Lung Cancer 2003; 42:97-102.
14. Philip PA. Gemcitabine and platinum combinations in pancreatic cancer. Cancer 2002; 95(4 suppl):908-911.
15. Tripathy D. Overview: gemcitabine as single-agent therapy for advanced breast cancer. Clin Breast Cancer 2002; 3(suppl 1):8-11.
16. Merriman RL, Hertel LW, Schutz RM, Houghton PJ, Houghton JA, Rutherford PG, et al. Comparison of the antitumor activity of gemcitabine and ara-C in a panel of human breast, colon, lung and pancreatic xenograft models. Invest New Drugs 1996; 14:243-247.
17. van Moorsel CJ, Pinedo HM, Veerman G, Vermorken JB, Postmus PE, Peters GJ. Scheduling of gemcitabine and cisplatin in Lewis lung tumor bearing mice. Eur J Cancer 1999; 35:808-814.
18. Riccardi A, Meco D, Ferlini C, Servidei T, Carelli G, Segni G, et al. In vitro and in vivo antitumor activity of the novel trinuclear platinum complex BBR 3464 in neuroblastoma. Cancer Chemother Pharmacol 2001; 47:498-504.
19. Klaassen CD (editor). Casarett and Doull's Toxicology: The Basic Science of Poisons, 6th edn. New York: McGraw-Hill; 2001, pp. 399-401, 496, 497, 500, 503, 506, 511, 695, 852, 853.
20. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002; 2:727-739.